Based on the WUXI BIOLOGICS-00000083 stock forecast from 0 analysts, the average analyst target price for WUXI BIOLOGICS-00000083 is not available over the next 12 months. WUXI BIOLOGICS-00000083’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of WUXI BIOLOGICS-00000083 is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, WUXI BIOLOGICS-00000083’s stock price was EUR 1.77. WUXI BIOLOGICS-00000083’s stock price has changed by -2.05% over the past week, -7.62% over the past month and -67.13% over the last year.
No recent analyst target price found for WUXI BIOLOGICS-00000083
No recent average analyst rating found for WUXI BIOLOGICS-00000083
Company Overview WUXI BIOLOGICS-00000083
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China. Read Less
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Aust...Read More
Frequently Asked Questions About WUXI BIOLOGICS-00000083 (1FW2:F) Stock
Stock Target Advisor's fundamental analysis for WUXI BIOLOGICS-00000083's stock is Neutral.
Unfortunately we do not have enough data on 1FW2:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 1FW2:F's stock to indicate what its average analyst target is.
1FW2:F stock's Price/Earning ratio is 22.63.
Our analysis grades 1FW2:F stock's Price / Earning ratio at F. This means that 1FW2:F stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the F exchange.
Based on this 1FW2:F may be a overvalued for its sector.
The last closing price of 1FW2:F's stock was EUR 1.77.
The most recent market capitalization for 1FW2:F is EUR 7.43B.
Unfortunately we do not have enough analyst data on 1FW2:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WUXI BIOLOGICS-00000083's stock.
As per our most recent records WUXI BIOLOGICS-00000083 has 12,435 Employees.
WUXI BIOLOGICS-00000083's registered address is No. 108, Meiliang Road, Wuxi, China, 214092.
You can get more information about it from WUXI BIOLOGICS-00000083's website at https://www.wuxibiologics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About WUXI BIOLOGICS-00000083 (1FW2:F) Stock
Stock Target Advisor's fundamental analysis for WUXI BIOLOGICS-00000083's stock is Neutral.
Unfortunately we do not have enough data on 1FW2:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 1FW2:F's stock to indicate what its average analyst target is.
1FW2:F stock's Price/Earning ratio is 22.63.
Our analysis grades 1FW2:F stock's Price / Earning ratio at F. This means that 1FW2:F stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the F exchange.
Based on this 1FW2:F may be a overvalued for its sector.
The last closing price of 1FW2:F's stock was EUR 1.77.
The most recent market capitalization for 1FW2:F is EUR 7.43B.
Unfortunately we do not have enough analyst data on 1FW2:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains WUXI BIOLOGICS-00000083's stock.
As per our most recent records WUXI BIOLOGICS-00000083 has 12,435 Employees.
WUXI BIOLOGICS-00000083's registered address is No. 108, Meiliang Road, Wuxi, China, 214092.
You can get more information about it from WUXI BIOLOGICS-00000083's website at https://www.wuxibiologics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 1FW2:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
